This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.


Advertisement


Mobile version  RSS  Subscribe  Unsubscribe  Archive  Media Kit

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us   May. 31, 2013


Advertisement

Advertisement

Advertisement
 

Advertisement

Discarded human kidneys as a source of ECM scaffold for kidney regeneration technologies
NCBI
In the United States, more than 2600 kidneys are discarded annually, from the total number of kidneys procured for transplant. It has been hypothesized that this organ pool may be used as a platform for renal bioengineering and regeneration research. The purpose of the current study was to test if the same strategy can be applied to discarded human kidneys in order to obtain human renal ECM scaffolds. The results show that the sodium dodecylsulfate-based decellularization protocol completely cleared the cellular compartment in these kidneys, while the innate ECM framework retained its architecture and biochemical properties.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  


Advertisement


SOCIETY NEWS


Evaluate your center's protocols for CMV disease
AST has endorsed a free, interactive online activity, Pathways in CMV Case Management. This CME/CE activity was developed by Spire Learning and is supported by an educational grant from Genentech. Learn how to evaluate your transplant center's protocols for preventing and managing CMV disease in transplant recipients, and how to select the appropriate strategies to prevent and manage CMV disease in adult and pediatric transplant recipients. Take part in this activity today.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Advertisement
PRODUCT SHOWCASE
  University of Utah - Multi-Organ Transplant Surgeon
The University Of Utah Department Of Surgery is seeking applications for a faculty member to join the multi-organ transplant team at the assistant professor level. This is an opportunity to join an expanding program and a cohesive group of transplant surgeons focused on excellence. The candidate should be board certified in general surgery and have completed an ASTS approved transplantation surgery fellowship. Apply here
 


Get your AST gear
We're pleased to now offer AST-branded apparel, exclusively from the AST Store! Pick up one of our new fleece jackets, polo shirts or baseball caps, embroidered with the AST logo. Items start at just $20!
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Save the Date for AST's Cutting Edge of Transplantation 2014
Are we on the right track with new drugs and biologics? Have the targets changed? Where can we really impact outcomes with "technology-omics?" The time has come to integrate our strategies, therapies and technology, and critically assess their merits as we face the enormous task of extending transplant survival. Save the date for the 2014 AST Cutting Edge of Transplantation, where expert clinicians, leading diagnosticians and world class scientists will address this enormous challenge together with an engaged audience.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Advertisement


AST Institutional Support Program
  • Are you interested in receiving recognition and increased exposure for your transplant center?
  • Does your center support the future of transplantation and value the educational, networking, and research opportunities that the American Society of Transplantation (AST) provides to its members?
  • Does your center support AST's lobbying of the U.S. Congress and Federal Agencies to secure a more transplant provider friendly environment for patients and physicians?
If the answer to these questions is YES, please consider having your center participate in AST's Institutional Support Program. With a charitable contribution of $3,000, your center will receive valuable benefits. For more information and to make a contribution, click here. All donations are tax-deductible.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Featured Advertisers


Advertisement
Astellas Pharma US, Inc.

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. For more information about Astellas Pharma US, Inc., please visit our Web site at www.astellas.us
Advertisement
New LIFECODES SSO Typing Kits

LIFECODES is introducing its new HLA-SSO kits. The new kit includes a validated, high-performance enzyme for improved reliability and performance with the continued ease of no centrifugation or wash steps; providing accurate, clear and easy to interpret results.
Advertisement
Genzyme


Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. MORE


TRANSPLANT NEWS


Short disease duration, worsening inflammatory bowel disease linked after liver transplantation
Healio
Liver transplant recipients with inflammatory bowel disease are more likely to experience worsening disease posttransplant with shorter disease duration, according to data presented at Digestive Disease Week. Researchers performed a retrospective chart analysis of 924 patients who underwent liver transplantation (LT) between 1998 and 2012. The cohort included 45 patients with posttransplant IBD, including 38 with previous IBD and seven who developed de novo IBD after the procedure. IBD severity was determined according to symptoms, complications, hospitalizations because of flares and use of steroids or immunosuppressive medications.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    Unclogging the pipeline of innovation in transplantation (AST)
Living donor size affects kidney transplant outcomes (Renal & Urology News)
Immune function assay (ImmuKnow) as a predictor of allograft rejection and infection in kidney transplantation (Clinical Transplantation)

Don't be left behind. Click here to see what else you missed.


Advertisement


Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections
Clinical Transplantation (login required)
Mycobacterium abscessus in cystic fibrosis (CF) patients is considered a contraindication to lung transplantation. A recent study examined the posttransplant outcomes of CF patients with M. abscessus pre-transplant.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Plasmacytoid dendritic cells: No longer an enigma and now key to transplant tolerance?
American Journal of Transplantation (login required)
Plasmacytoid (p) dendritic cells (DC) are a specialized subset of DC whose primary role was initially defined by the production of type I interferons in response to viral infection. They are now known to also possess a repertoire of functions capable of determining T cell fate and activation. Under homeostatic conditions, non-lymphoid tissue-resident pDC play a critical role in the regulation of mucosal immunity, as well as the development of central and peripheral tolerance. Although these cells display a number of characteristics that differ from conventional DC, particularly altered costimulatory molecule expression and poor allostimulatory capacity when interacting with T cells, this phenotype favors the generation of alloantigen-specific regulatory CD4+ or CD8+ T cells critical to the development of graft tolerance. This minireview details pDC ontogeny, functional biology and the emerging data that demonstrate the importance of pDC in the induction of tolerance, as well as recent studies that define mechanisms underlying pDC-mediated tolerance to both solid organ and haematopoietic stem cell transplants.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Featured Advertisers


Advertisement
Put Science on Your Side

Drug Monitoring Platforms since 1981.

Learn More
Advertisement
Exclusively Focused Transplant Pharmacy Therapeutics
Transplant IV Biologics and Oral Immunosuppressives specializing in Desensitization and AMR Treatment and Prevention. MORE


Trial: Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients
Clinical Transplantation (login required)
In a recent clinical trial, researchers compared in kidney transplantation two immunosuppressive regimens: Tacrolimus plus mycophenolate mofetil (MMF) (TAC) and everolimus plus low-dose cyclosporine (EVE). Sixty consecutive patients received TAC (30 patients) or EVE (30 patients) as immunosuppressive regimen; all subjects also received induction with basiliximab and corticosteroids.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement


Long-term follow-up of endoscopic therapy for stenosis of the biliobiliary anastomosis associated with orthotopic liver transplantation
Liver Transplantation (login requied)
Endoscopic treatment for stenosis of an anastomotic biliary stricture (ABS) after orthotopic liver transplantation (OLT) has been proven to be effective and safe, but the long-term outcomes and the risk factors for recurrence are unknown. All 374 patients who underwent OLT at Frankfurt University Hospital were screened for the occurrence of ABSs.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Human adipose-derived mesenchymal stem cells can survive and integrate into the adult rat eye following xenotransplantation
Xenotransplantation (login required)
Novel threads of discovery provide the basis for optimism for the development of a stem-cell-based strategy for the treatment of retinal blindness. Accordingly, achievement to suitable cell source with potential-to-long-term survival and appropriate differentiation can be an effective step in this direction.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Courtney Hodges, Content Editor, 972.402.2604   
Contribute news


This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
May 24, 2013
May 17, 2013
May 10, 2013
May 3, 2013






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063